MRKR

Marker is a pre-revenue, clinical-stage immuno-oncology company whose 10-K explicitly flags "substantial doubt regarding our ability to continue as a going concern." Management is blunt that it has "no approved products," has "not derived any revenue from the sales of products," and expects losses "for the indefinite future." The $3.55M of FY2025 revenue is grant/collaboration income, not commercial sales — so the headline P/S of 6.9x is economically meaningless, and that revenue still fell 46.2% YoY. Net loss of $12.2M on operating cash flow of -$12.0M against $16.1M of cash implies roughly 1.3 years of runway before another raise, and the accumulated deficit of -$459M shows how much capital this platform has already consumed.

The capital structure confirms the squeeze. Shares outstanding jumped 55.7% in a single year, diluting existing holders heavily just to keep the lights on; with cash down 16.3% and a burn that management says will "increase significantly" as clinical programs advance, further dilution or financing on unfavorable terms is close to certain. The balance sheet looks superficially clean (liabilities/equity 0.14x, minimal debt), but that equity is being steadily eroded by losses — stockholders' equity fell 9.5% to $16.8M and is almost entirely the shrinking cash pile. ROE of -72.4% and margins near -350% are not signals of operating leverage to come; they are the arithmetic of a company with costs and no product.